Xarelto纳入医保了吗？

Rivaroxaban (Xarelto) is a highly selective, oral drug that directly inhibits factor Xa. By inhibiting factor Rivaroxaban (Xarelto) does not inhibit thrombin (activated factor II) and has not been shown to have an effect on platelets. Rivaroxaban (Xarelto) is clinically indicated for the prevention of venous thrombosis (VTE) in adult patients undergoing elective hip or knee replacement surgery. Its main mechanism of action is: inhibitory factor Xa can interrupt the endogenous and exogenous pathways of the coagulation cascade and inhibit the generation of thrombin and thrombosis. Rivaroxaban (Xarelto) can interrupt the intrinsic and extrinsic pathways of the coagulation cascade by inhibiting factor Xa, inhibiting thrombin generation and thrombosis. Rivaroxaban (Xarelto) does not inhibit thrombin (activated factor II) and has not been shown to have an effect on platelets. A dose-dependent inhibitory effect of rivaroxaban (Xarelto) on factor Xa activity has been observed in humans. Clinical studies have shown that rivaroxaban (Xarelto) can effectively prevent deep vein thrombosis after peri-hip fracture surgery. It has good safety and is worthy of clinical promotion.   

Rivaroxaban (Xarelto) received marketing approval in Canada and the European Union on September 15 and October 1, 2008, respectively. On July 1, 2011, the FDA approved rivaroxaban (Xarelto) for the prevention of deep vein thrombosis in patients undergoing knee or hip replacement surgery. In March 2009, rivaroxaban (Xarelto) was approved for marketing by the State Food and Drug Administration, and was successfully included in the 2009 National Medical Insurance List in the same year.